Breast Cancer—Local/Regional/Adjuvant

Oncoletter provides you with the abstract's links. To see more, go the ASCO Meeting Library while clicking on the link of the study-titles (to see videos and slides needs a payable registration)

William J. Gradishar: ASCO 2020 Report — Breast Cancer  Highlights of the latest treatments

500 Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC).

Nadia Harbeck, Seock-Ah Im, Carlos H. Barrios, et al. (Interview mit Nadia Harbeck HIER)

Clinical trial information: NCT01966471.

See the report in the ASCO DAILY NEWS: 

T-DM1 Does Not Improve Safety or Efficacy in HER2-Positive Early Breast Cancer; Favorable iDFS Reported

--------------------------------------------------------------------------------------------------------------------------------------------------------

501 Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2-positive breast cancer (TRAIN-2): A randomized phase III trial.

Anna van der Voort, Mette S. van Ramshorst, Erik D. van Werkhoven, et al

Clinical trial information: NCT01996267.

See the report about Abstract 501 & 503 in the ASCO DAILY NEWS:

Strategies Emerge for Chemotherapy De-escalation in HER2-Positive Breast Cancer

--------------------------------------------------------------------------------------------------------------------------------------------------------

502 Biomarker data from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer.

Carsten Denkert, Chiara Lambertini, Peter A. Fasching, et al.

Clinical trial information: NCT01772472.

--------------------------------------------------------------------------------------------------------------------------------------------------------

503 Chemotherapy (CT) de-escalation using an FDG-PET/CT (F-PET) and pathological response-adapted strategy in HER2[+] early breast cancer (EBC): PHERGain Trial.

Javier Cortes, Geraldine Gebhart, Manuel Ruiz Borrego, et al.

Clinical trial information: NCT03161353.

--------------------------------------------------------------------------------------------------------------------------------------------------------

504 ALTERNATE:  Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106.

Cynthia X. Ma, Vera J. Suman, A. Marilyn Leitch, et al. (Interview zum Thema mit Christian Jackisch, Offenbach)

Clinical trial information: NCT01953588.

--------------------------------------------------------------------------------------------------------------------------------------------------------

505 Letrozole + ribociclib versus letrozole + placebo as neoadjuvant therapy for ER+ breast cancer (FELINE trial).

Qamar J. Khan, Anne O'Dea, Aditya Bardia, et al. (Interview zum Thema mit Christian Jackisch, Offenbach)

Clinical trial information: NCT02712723.

--------------------------------------------------------------------------------------------------------------------------------------------------------

506 MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients.

Fatima Cardoso, Laura van 't Veer, Coralie Poncet, et al. (Interview zum Thema mit Christian Jackisch, Offenbach)

Clinical trial information: NCT00433589.

--------------------------------------------------------------------------------------------------------------------------------------------------------

507 Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

XI Wang, Shu-Sen Wang, Heng Huang, et al. (Interview zur Studie mit Michael Untch, Berlin-Buch)

Clinical trial information: NCT01112826.

--------------------------------------------------------------------------------------------------------------------------------------------------------

508 Primary results of NRG Oncology / NSABP B-43: Phase III trial comparing concurrent trastuzumab (T) and radiation therapy (RT) with RT alone for women with HER2-positive ductal carcinoma in situ (DCIS) after lumpectomy.

Melody A. Cobleigh, Stewart J. Anderson, Kalliopi P. Siziopikou, et al.

Clinical trial information: NCT00769379.

--------------------------------------------------------------------------------------------------------------------------------------------------------

Highlighted abstract from the poster session:

Poster Session

584 Inhibiting fatty acid synthase in operable triple negative breast cancer.

Sagar D. Sardesai, Alexandra Thomas, Christopher Gallagher, et al. 

Clinical trial information: NCT02595372.